ALSA Ventures launches novel Gene Therapy portfolio company Axovia Therapeutics to treat Ciliopathies
LONDON, Sept. 19, 2023 (GLOBE NEWSWIRE) -- ALSA Ventures , a UK-based, therapeutics-focused venture capital fund, announces the acquisition of Axovia Therapeutics Inc and the launch of a new portfolio company Axovia Therapeutics Ltd .
- LONDON, Sept. 19, 2023 (GLOBE NEWSWIRE) -- ALSA Ventures , a UK-based, therapeutics-focused venture capital fund, announces the acquisition of Axovia Therapeutics Inc and the launch of a new portfolio company Axovia Therapeutics Ltd .
- Axovia is developing the first gene therapies for ciliopathies and has a pipeline of products for these devastating diseases, including Bardet-Biedl Syndrome (BBS).
- AXV101 is an AAV9-based gene therapy targeting retinal dystrophy associated with BBS in patients carrying biallelic mutations in the BBS1 gene.
- Axovia Acting CEO Professor Phil Beales said the Axovia gene therapy platform gives hope to BBS patients worldwide.